4 0 9 5 7

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊










更多详情 >>



会员计划

我们很高兴为机构提供一种切实的方法以支持开放获取并鼓励教师和研究人员通过开放获取模式尽可能广泛地传播他们的作品。

更多详情 >>

 

加入德孚官方微信,即可享受论文费用7.5折

已发表论文

CXCR2 是一种用于三阴性乳腺癌的新型癌症干细胞标记物

 

Authors Wang Y, Tu L, Du C, Xie X, Liu Y, Wang J, Li Z, Jiang M, Cao D, Yan X, Luo F

Received 16 May 2018

Accepted for publication 22 June 2018

Published 6 September 2018 Volume 2018:11 Pages 5559—5567

DOI https://doi.org/10.2147/OTT.S174329

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Sanjeev Srivastava

Background: Breast cancer is the leading cause of mortality from cancer in women worldwide, and cancer stem-like cell (CSC) is responsible for failure treatment of breast cancer. It plays an important role in resistant disease and metastasis. CD44/CD24 and ALDH are well-accepted protein markers of breast CSC, and it was reported that distinct subtypes of breast CSC were identified by the 2 markers. It is possible that there are various kinds of breast CSC which could be identified by different markers, and CSC markers utilized at present are not enough to fully understand breast CSC. Finding out more novel CSC markers is necessary. CXCR2 is involved in breast cancer metastasis, treatment resistance, and recurrence and has positive cross-talk with known breast CSC protein markers. It can be concluded that CXCR2 is related to breast CSC, and further study is in need.
Results: In this study, we assessed expression of CXCR2 with immunohistochemistry in breast cancer tissues from 37 patients and discovered that level of CXCR2 was significantly lower in triple-negative breast cancer (TNBC) compared with non-TNBC. CXCR2 expression decreased in estrogen receptor-negative or HER2-negative breast cancer, but not progesterone receptor-negative counterparts. By immunofluorescence, we observed high coexpression rate of CXCR2 and CSC-related proteins, including NANOG and SOX2. To prove our speculation that CXCR2 was a novel CSC marker for TNBC, we used 4T1 cell, which is a TNBC cell line, to analyze CXCR2-positive subpopulations and observed that CXCR2-positive 4T1 cells showed characteristics of CSC, including resistance to cisplatinum, radiation, and hypoxia, low proportion (around 1%), much more tumor xenografts, tumor spherule formation, and higher levels of CSC-related mRNA compared with CXCR2-negative cells.
Conclusion: CXCR2 is an acceptable and newly discovered CSC marker for only TNBC.
Keywords: cancer stem-like cell, CXCR2, triple-negative breast cancer, marker




Figure 3 CXCR2 is a novel cancer stem-like cell marker for 4T1 breast cancer cells.